Radiopharmaceutical developer Navidea Biopharmaceuticals has closed a $25 million debt financing transaction led by GE Capital's Healthcare Financial Services division.
The loan will be used to support commercialization of the company's Lymphoseek product, to advance the clinical development of Navidea's pipeline, and to repay its existing outstanding debts, according to Navidea.
The funding closed on June 25, Navidea said.
